BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 29923178)

  • 1. Effects of psilocybin therapy on personality structure.
    Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL
    Acta Psychiatr Scand; 2018 Nov; 138(5):368-378. PubMed ID: 29923178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
    Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
    Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
    Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effects of ayahuasca on personality structure in a traditional framework.
    Netzband N; Ruffell S; Linton S; Tsang WF; Wolff T
    Psychopharmacology (Berl); 2020 Oct; 237(10):3161-3171. PubMed ID: 32700023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NEO-FFI domain of openness to experience moderates ketamine response in treatment resistant depression.
    Dale RM; Bryant KA; Finnegan N; Cromer K; Thompson NR; Altinay M; Anand A
    J Affect Disord; 2020 Jan; 260():323-328. PubMed ID: 31521869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
    McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
    J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
    Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
    JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
    Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
    J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
    Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
    Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
    Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Psychol Med; 2024 Jan; 54(1):178-192. PubMed ID: 37264814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep brain stimulation of the supero-lateral branch of the medial forebrain bundle does not lead to changes in personality in patients suffering from severe depression.
    Bewernick BH; Kilian HM; Schmidt K; Reinfeldt RE; Kayser S; Coenen VA; Markett S; Schlaepfer TE
    Psychol Med; 2018 Dec; 48(16):2684-2692. PubMed ID: 29493478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hidden therapist: evidence for a central role of music in psychedelic therapy.
    Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R
    Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial.
    Knorr U; Vinberg M; Mortensen EL; Winkel P; Gluud C; Wetterslev J; Gether U; Kessing LV
    PLoS One; 2012; 7(2):e31980. PubMed ID: 22393376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.